R. Malayeri
Impact in
- Oncology top 10%
- Lung Cancer Research Studies
- Drug Transport and Resistance Mechanisms
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 14
- Lung Cancer Research Studies 6
- Cancer Treatment and Pharmacology 3
- Drug Transport and Resistance Mechanisms 2
- Colorectal Cancer Treatments and Studies 2
-
- Lung Cancer Treatments and Mutations 11
- Lung Cancer Diagnosis and Treatment 6
- Co-authors
- Robert Pirker (15 shared papers)Kurt Krejcy (3 shared papers)Sabine Zöchbauer‐Müller (6 shared papers)C. Manegold (1 shared paper)Joachim von Pawel (1 shared paper)U. Gatzemeier (1 shared paper)J. Blatter (1 shared paper)H. Huber (9 shared papers)
In The Last Decade
R. Malayeri
20 papers receiving 423 citations
Peers
Comparison fields: 5 of 55
- Oncology 226
- Pulmonary and Respiratory Medicine 187
- Immunology 70
- Hematology 20
- Cancer Research 19
Countries citing papers authored by R. Malayeri
This map shows the geographic impact of R. Malayeri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Malayeri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Malayeri more than expected).
Fields of papers citing papers by R. Malayeri
This network shows the impact of papers produced by R. Malayeri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Malayeri. The network helps show where R. Malayeri may publish in the future.
Co-authors
The 25 scholars most cited alongside R. Malayeri, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2000 | 128 | |
| 2 | 2005 | 88 | |
| 3 | 1995 | 46 | |
| 4 | 2000 | 34 | |
| 5 | 1996 | 28 | |
| 6 | Expression of the multidrug resistance protein (MRP1) in breast cancer. | 2000 | 27 |
| 7 | Clinical relevance of drug resistance genes in malignant disease. | 1996 | 22 |
| 8 | 1998 | 20 | |
| 9 | 2006 | 8 | |
| 10 | Phase II trial of gemcitabine in advanced non-small-cell lung cancer. | 1997 | 6 |
| 11 | 2001 | 5 | |
| 12 | 2015 | 4 | |
| 13 | 1999 | 4 | |
| 14 | 2008 | 3 | |
| 15 | 2000 | 3 | |
| 16 | 2017 | 2 | |
| 17 | 1997 | 2 | |
| 18 | 2016 | 1 | |
| 19 | 1997 | 1 | |
| 20 | [Gemcitabine and cisplatin as induction therapy for patients with histologically proven stage IIIA-N2 non-small-cell bronchial cancer: a phase-II study of the EORTC Cooperative Group (EORTC 08955)]. | 2001 | 1 |
About R. Malayeri
R. Malayeri is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Public Health, Environmental and Occupational Health and Hematology, having authored 21 papers that have together received 433 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (6 papers), Lung Cancer Diagnosis and Treatment (6 papers), Cancer Treatment and Pharmacology (3 papers), Cancer therapeutics and mechanisms (2 papers), Drug Transport and Resistance Mechanisms (2 papers), Palliative Care and End-of-Life Issues (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). The work is most often cited by research in Oncology (226 citations), Pulmonary and Respiratory Medicine (187 citations), Immunology (70 citations), Hematology (20 citations) and Cancer Research (19 citations). R. Malayeri has collaborated with scholars based in Austria, Iran and Germany. Frequent co-authors include Robert Pirker, Kurt Krejcy, Sabine Zöchbauer‐Müller, C. Manegold, Joachim von Pawel, U. Gatzemeier, J. Blatter, H. Huber, G. Krajnik and Martin Filipits. Their work appears in journals such as Annals of Oncology, Lung Cancer, European Journal of Cancer, Immunology and Journal of Thoracic Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.